EchiTAB+ICP Antivenom

Info
Statistics
Created: 11/23/12
Last Edited: 01/17/13
465
22
1
Description
Branding for EchiTAb study group was created by the united front of the Liverpool School of Tropical Studies, Oxford University, Ministry of Health of Nigeria and Instituto Clodomiro Picado.
  • EchiTAb study group was created by the united front of the Liverpool School of Tropical Studies, Oxford University, Ministry of Health of Nigeria and Instituto Clodomiro Picado. The Clodomiro Picado Institute has been carrying out research on herpetofauna for the past 40 years. Its activities include the following: research on toxins from venomous animals in Latin America, and on snake venoms; and basic and applied research on immunobiologicals, particularly antivenoms for envenomings following snakebites. The Institute is attached to the University of Costa Rica, where it coordinates graduate and postgraduate courses in the fields of biochemistry, immunology, herpetology and research. It also supervises student theses in these research areas.

    The Clodomiro Picado Institute produces antivenoms for many Central and South American and European countries. It has developed innovative scientific and biotechnical processes to promote the enhancement of biologicals, both nationally and internationally; it advises countries on the prevention and treatment of snakebites, and also the production and quality control of antivenoms in Central and South America; and it manages collaboration projects for the production of antivenoms specific to countries with scarce resources such as Nigeria, Papua New Guinea and Sri Lanka. In collaboration with the Latin American science and technology development programme (CYTED), the Clodomiro Picado Institute coordinates a network of production and quality-control centres in Central and South America.

    The Institute was involved in the drafting of the WHO guidelines for the production, control and regulation of snake antivenom immunoglobulins.

Discuss This Project: ( Comments)

You must to join the conversation.